Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Share-based Compensation (2020 - 2024)

Immuneering (IMRX) has 5 years of Share-based Compensation data on record, last reported at $1.7 million in Q4 2024.

  • For Q4 2024, Share-based Compensation rose 5.13% year-over-year to $1.7 million; the TTM value through Dec 2024 reached $6.5 million, up 13.52%, while the annual FY2024 figure was $6.5 million, 13.52% up from the prior year.
  • Share-based Compensation reached $1.7 million in Q4 2024 per IMRX's latest filing, up from $1.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.7 million in Q4 2024 and bottomed at $182225.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $1.0 million, with a median of $1.1 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: soared 392.61% in 2022, then increased 5.13% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $216607.0 in 2020, then skyrocketed by 192.04% to $632583.0 in 2021, then soared by 65.7% to $1.0 million in 2022, then surged by 56.52% to $1.6 million in 2023, then increased by 5.13% to $1.7 million in 2024.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $1.7 million in Q4 2024, $1.6 million in Q3 2024, and $1.7 million in Q2 2024.